1 Soaring Stock Boasting Strong Fundamentals and 2 We Steer Clear Of

Are High-Priced Stocks Worth the Hype?

Stocks with premium valuations often achieve these heights thanks to impressive growth that sets them apart from the competition. However, such high expectations can make them especially vulnerable when investor sentiment turns negative.

Striking the right balance between value and quality is a challenge for even the most experienced investors. That’s why StockStory exists—to help you uncover genuine investment opportunities. With that in mind, here’s one standout stock to consider holding for the long haul, and two that may be facing significant headwinds.

Two Overvalued Stocks to Consider Selling

Five Below (FIVE)

Forward P/E Ratio: 33.4x

Five Below (NASDAQ:FIVE) is a U.S.-based discount retailer known for its “treasure hunt” shopping experience, offering a wide range of products—like phone accessories, candy, and sporting goods—primarily priced at $5 or less.

Concerns About FIVE

• With annual revenue of $4.43 billion, Five Below lacks the scale and distribution reach of larger competitors, limiting its ability to leverage fixed costs.
• The company’s low gross margin of 35.4% reflects intense competition, commoditized inventory, and challenging unit economics.
• A modest 10.4% return on capital signals management’s struggle to find profitable growth avenues, and declining returns suggest its core profit drivers are losing steam.

Currently, Five Below trades at $222.45 per share, equating to a forward P/E of 33.4.

Corcept Therapeutics (CORT)

Forward P/E Ratio: 94.4x

Corcept Therapeutics (NASDAQ:CORT) develops and markets medications that target cortisol, the body’s primary stress hormone, to treat a range of conditions including endocrine disorders, cancer, and neurological diseases.

Why CORT Faces Challenges

• Although revenue has grown over the past five years, earnings per share have declined by 6.9% annually, indicating that new sales have been less profitable.
• The company’s free cash flow margin has dropped by 27.1 percentage points in five years, reflecting heavier investments to maintain its market position.
• Falling returns on capital suggest that Corcept’s most lucrative opportunities may be behind it.

Corcept shares are priced at $33.16, representing a forward P/E of 94.4.

One High-Potential Stock to Buy

Fair Isaac Corporation (FICO)

Forward P/E Ratio: 32x

Fair Isaac Corporation (NYSE:FICO) is best known for creating the FICO Score, the industry standard for assessing consumer credit risk in the U.S., and for developing advanced analytics software used by lenders nationwide.

Why FICO Stands Out

• Share buybacks over the past two years have helped annual earnings per share grow by 24.6%, outpacing revenue growth.
• A robust free cash flow margin of 34.8% gives FICO the flexibility to reinvest or return capital to shareholders.
• Returns on capital are on the rise as management continues to make strategic, high-return investments.

Trading at $1,291 per share with a forward P/E of 32, FICO may be a compelling addition to your portfolio.

Discover Even More Top Stocks

WHILE YOU’RE HERE: Our Top 9 Market-Beating Stocks
The most successful stocks don’t just outperform once—they do it repeatedly. These companies boast strong revenue growth, expanding free cash flow, and exceptional returns on capital, consistently outpacing their peers. The market has already recognized their strength.

But according to our AI-driven analysis, these stocks still have room to run. Curious which nine made the list this week?

Past picks include well-known names like Nvidia (up 1,326% from June 2020 to June 2025) and lesser-known companies such as Kadant, which delivered a 351% return over five years.